TY - JOUR
T1 - DNA methylation as a triage tool for cervical cancer screening – A meeting report
AU - Burdier, F. Ricardo
AU - Waheed, Dur e.Nayab
AU - Nedjai, Belinda
AU - Steenbergen, Renske D.M.
AU - Poljak, Mario
AU - Baay, Marc
AU - Vorsters, Alex
AU - Van Keer, Severien
N1 - Publisher Copyright: © 2024 The Authors
PY - 2024/5
Y1 - 2024/5
N2 - Introduction: DNA methylation is proposed as a novel biomarker able to monitor molecular events in human papillomavirus (HPV) infection pathophysiology, enabling the distinction between HPV-induced lesions with regression potential from those that may progress to HPV-related cancer. Methods: This meeting report summarises the presentations and expert discussions during the HPV Prevention and Control Board-focused topic technical meeting on DNA methylation validation in clinician-collected and self-collected samples, novel DNA methylation markers discovery, implementation in cervical cancer screening programs, and their potential in women living with human immunodeficiency virus (HIV). Results: Data presented in the meeting showed that HPV-positive, baseline methylation-negative women have a lower cumulative cervical cancer incidence than baseline cytology-negative women, making DNA methylation an attractive triage strategy. However, additional standardised data in different settings (low- versus high-income settings), samples (clinician-collected and self-collected), study designs (prospective, modelling, impact) and populations (immunocompetent women, women living with HIV) are needed. Conclusion: Establishing international validation guidelines were identified as the way forward towards accurate validation and subsequent implementation in current screening programs.
AB - Introduction: DNA methylation is proposed as a novel biomarker able to monitor molecular events in human papillomavirus (HPV) infection pathophysiology, enabling the distinction between HPV-induced lesions with regression potential from those that may progress to HPV-related cancer. Methods: This meeting report summarises the presentations and expert discussions during the HPV Prevention and Control Board-focused topic technical meeting on DNA methylation validation in clinician-collected and self-collected samples, novel DNA methylation markers discovery, implementation in cervical cancer screening programs, and their potential in women living with human immunodeficiency virus (HIV). Results: Data presented in the meeting showed that HPV-positive, baseline methylation-negative women have a lower cumulative cervical cancer incidence than baseline cytology-negative women, making DNA methylation an attractive triage strategy. However, additional standardised data in different settings (low- versus high-income settings), samples (clinician-collected and self-collected), study designs (prospective, modelling, impact) and populations (immunocompetent women, women living with HIV) are needed. Conclusion: Establishing international validation guidelines were identified as the way forward towards accurate validation and subsequent implementation in current screening programs.
KW - Cervical cancer screening
KW - HPV-related disease
KW - Human papillomavirus infection
KW - Methylation
KW - Molecular biomarker
KW - Prognostic biomarker
KW - Self-sampling
KW - Triage
UR - http://www.scopus.com/inward/record.url?scp=85188001670&partnerID=8YFLogxK
U2 - 10.1016/j.pmedr.2024.102678
DO - 10.1016/j.pmedr.2024.102678
M3 - Review article
C2 - 38524273
SN - 2211-3355
VL - 41
JO - Preventive medicine reports
JF - Preventive medicine reports
M1 - 102678
ER -